This actively managed Exchange Traded Fund (ETF) endeavors to meet its investment goals by typically allocating a minimum of 80% of its total net assets (including any capital secured through borrowing for investment purposes) into the securities of specific companies. To be eligible for inclusion, these companies must either derive at least half of their net revenue from, or commit 50% or more of their assets to, psychedelic compounds, their derivatives, or other financial instruments exhibiting similar economic characteristics. The fund's primary holdings consist of publicly traded life sciences firms focused on psychedelic medical treatments, in addition to other businesses involved in the broader psychedelics sector. It is important to note that this fund maintains a concentrated, non-diversified portfolio.

Asset class

Equity

Issuer

AdvisorShares

Domicile

US

Inception date

Sep 15, 2021

Holdings

25

ISIN

US00768Y2972